Codexis, INC

Codexis, Inc. announced the successful closing of its public offering of common stock, raising approximately $23.1 million in net proceeds.

Codexis, Inc. announced preliminary financial results for the second quarter of 2026, expecting at least $14.8 million in revenue and approximately $54.9 million in cash.

Codexis announces board realignments including a director's resignation and subsequent re-election to rebalance board classes.

Codexis announced a strategic realignment, including a 24% workforce reduction, new CEO appointment, and a $37.8 million Merck agreement, extending its cash runway through 2027.

Codexis, Inc. announced strong second quarter 2025 financial results, exceeding analyst revenue estimates and strengthening its cash position to advance its ECO Synthesis platform.

Codexis, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the re-election of two directors and an amendment to expand the 2019 Incentive Award Plan by 8 million shares.

Codexis, Inc. announced its first quarter 2026 financial results, reporting a significant increase in total revenues driven by strong growth in research and development revenue.

Codexis reports a decrease in total revenues for Q3 and YTD 2025, alongside a narrower net loss, as it focuses on its ECO Synthesis platform and implements a workforce reduction.

Codexis, Inc. reported a significantly reduced net loss in the second quarter of 2025, driven by a substantial increase in research and development revenue and improved product gross margins, despite a year-to-date revenue decline.

Codexis' Q1 2025 results reveal a significant drop in revenue, primarily due to lower product and research and development revenue, as the company focuses on its pharma biocatalysis business and ECO Synthesis platform.

Codexis saw a significant jump in product revenue during the third quarter of 2024, but overall losses continued due to decreased research and development revenue and increased operating expenses.

Codexis, Inc. reports a significant decrease in revenue for the second quarter of 2024, driven by lower product sales and research and development revenue, as the company focuses on its core pharmaceutical manufacturing business and ECO Synthesis platform.

Codexis, Inc. announces its 2024 financial results, highlighting its strategic focus on pharma biocatalysis and the ECO Synthesis manufacturing platform for RNAi therapeutics.

Codexis's annual 10-K filing details its share structure, strategic shift towards pharmaceutical manufacturing and RNAi therapeutics, and discontinuation of certain biotherapeutic programs.

H. Stewart Parker, a Director at Codexis, Inc., acquired 66,350 stock options with an exercise price of $2.48.

Cynthia Collins, a Director at Codexis, Inc., acquired stock options granting the right to buy 66,350 shares.

Codexis Director Christos Richards acquired 66,350 stock options with an exercise price of $2.48, vesting on June 17, 2026.

David V. Smith, a Director at Codexis, Inc., acquired 66,350 stock options with an exercise price of $2.48, vesting on June 17, 2026.

Director Rahul Singhvi of Codexis, Inc. reported the acquisition of stock options, indicating a vested interest in the company's future performance.

Codexis, Inc. director Esther Martinborough acquired stock options for 66,350 shares of common stock.

Codexis, Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 10, 2025, outlining proposals including the election of directors, ratification of the company's independent auditor, approval of executive compensation, and an amendment to the 2019 Incentive Award Plan.

Codexis is holding its annual meeting on June 10, 2025, to vote on director elections, auditor ratification, executive compensation, and an amendment to the incentive award plan.

Codexis, Inc. is holding its annual stockholder meeting on June 11, 2024, and has made proxy materials available for review and voting.

Codexis, Inc. will hold its annual stockholders meeting virtually on June 11, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Telemark Asset Management, LLC, Telemark Fund, LP, and Colin S. McNay have jointly filed a Schedule 13G, reporting beneficial ownership of 7.3% of Codexis, Inc. common stock.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 7.45% in Codexis, Inc. common stock.

Millennium Management LLC and affiliated entities have reported beneficial ownership of 5.2% of Codexis, Inc. common stock.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership of Codexis Inc. common stock following an internal realignment.

Opaleye Management Inc., Opaleye, L.P., and James Silverman collectively report a 7.52% passive beneficial ownership in Codexis, Inc. common stock.

Aberdeen Group plc and its subsidiary abrdn Inc. reported a combined beneficial ownership of 8.82% of Codexis, Inc.'s common stock as of December 31, 2025.